linvoseltamab + dupilumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy
Trial Timeline
May 17, 2024 → Mar 28, 2028
NCT ID
NCT06369467About linvoseltamab + dupilumab
linvoseltamab + dupilumab is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Food Allergy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06369467. Target conditions include Food Allergy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06369467 | Phase 1 | Recruiting |
Competing Products
17 competing products in Food Allergy